Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream?Phase 3 Open Label Extension Study in Plaque Psoriasis

??WESTLAKE VILLAGE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced it has enrolled the first patient in an open label extension study, DERMIS-OLE, evaluating topical roflumilast cream (ARQ-151) as a potential treatment for plaque psoriasis.? Roflumilast cream, Arcutis? lead product candidate, is a highly potent and selective phosphodiesterase type 4 inhibitor (?PDE4 inhibitor?) once-daily topical cream.